ADMA Biologics, Inc. (ADMA) Starts Presentation at 2015 Marcum MicroCap Conference

ADMA Biologics develops, manufactures and intends to market specialty plasma-based biologics to treat and prevent certain infectious diseases. ADMA’s mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-compromised for medical reasons. For more information, visit the company’s website at www.admabiologics.com.